Market Overview:
The global paroxysmal nocturnal hemoglobinuria (PNH) treatment market is expected to register a CAGR of XX% during the forecast period 2018-2030. The market growth can be attributed to the increasing prevalence of PNH, rising awareness about PNH and its diagnosis, and technological advancements in the field of PNH treatment. Based on type, the global paroxysmal nocturnal hemoglobinuria (PNH) treatment market is segmented into ACH-4471, ALN-CC5, ALXN-1210, AMY-101, APL-2 and others. Among these types, ACH 4471 held a dominant share in 2017 and is projected to maintain its dominance during the forecast period. This can be attributed to its high efficacy as well as safety profile. Based on application, the global paroxysmal nocturnal hemoglobinuria (PNH) treatment market is segmented into hospital care settings; clinic care settings; homecare settings; research laboratories; and others including military hospitals & prisons etc.). Among these applications segments hospital care setting held a dominant share in 2017 and it is projected that this trend would continue throughout the forecast period 2018–2030.
Product Definition:
Paroxysmal Nocturnal Hemoglobinuria Treatment is the process of treating patients that suffer from Paroxysmal Nocturnal Hemoglobinuria. This treatment is important because it can help improve the patient's quality of life and help them live a healthier life.
ACH-4471:
ACH-4471 is a novel oral hypoxia prodrug developed by the pharmaceutical company named as Achaogen. It’s an oxygenation agent that works by increasing the amount of oxygen delivered to tissues when it is given to patients with chronic obstructive pulmonary disease (COPD) and sleep apnea.
ALN-CC5:
ALN-CC5 is a novel, potential therapeutic drug for the treatment of patients with PNH. It is an investigational compound currently in phase II clinical trials. The current standard of care for PNH involves blood transfusions and iron chelation therapy which are both associated with significant side effects such as adverse effects related to transfusion including hemoglobinopathy, allergic reactions, and infectious complications along with toxicity due to excess metal in the body.
Application Insights:
The hospital application segment led the market in 2017 and is projected to expand at a revenue-based CAGR of XX% over the forecast period owing to rising cases of PNH being diagnosed in hospitals due to better awareness about diagnosis and treatment. Moreover, increasing number of research studies regarding new drugs for paroxysmal nocturnal hemoglobinuria (PNH) is expected to drive the hospital segment over the forecast period.
Clinic applications accounted for 22% share of total revenue in 2017 owing to high prevalence of PNH across various regions coupled with availability of advanced therapies that are cost-effective as compared with other therapeutic options available for PNH patients such as blood transfusion centers or dialysis facilities near their residences which help them access healthcare services easily without having travel complications or financial limitations imposed by insurance companies.
Regional Analysis:
North America held the largest share in 2016 owing to the presence of key players and well-established healthcare infrastructure. The U.S.-based company, Novartis AG is engaged in drug development activities for Paroxysmal Nocturnal Hemoglobinuria (PNH) treatment. It has several ongoing and completed clinical trials for PNH treatment using its pipeline products such as ACH-4471, ALN-CC5, and others.
Asia Pacific is expected to be fastest growing region over the forecast period due to increasing number of patients suffering from PNH coupled with rising awareness about available treatments among people affected by this rare disease.
Growth Factors:
- Increasing incidence of Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Growing demand for novel therapies for PNH treatment
- Rising awareness about PNH and its treatment options
- Availability of government funding for research on PNH treatments
- Technological advancements in the field of hemoglobinopathy treatments
Scope Of The Report
Report Attributes
Report Details
Report Title
Paroxysmal Nocturnal Hemoglobinuria Treatment Market Research Report
By Type
ACH-4471, ALN-CC5, ALXN-1210, AMY-101, APL-2, Others
By Application
Hospital, Clinic, Others
By Companies
Achillion Pharmaceuticals Inc, Akari Therapeutics Plc, Alexion Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc, Amgen Inc, Apellis Pharmaceuticals Inc, F. Hoffmann-La Roche Ltd, ISU ABXIS Co Ltd, Novartis AG, NovelMed Therapeutics Inc, Omeros Corp, Ra Pharmaceuticals Inc, Regeneron Pharmaceuticals Inc, Regenesance BV
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
177
Number of Tables & Figures
124
Customization Available
Yes, the report can be customized as per your need.
Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Report Segments:
The global Paroxysmal Nocturnal Hemoglobinuria Treatment market is segmented on the basis of:
Types
ACH-4471, ALN-CC5, ALXN-1210, AMY-101, APL-2, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Achillion Pharmaceuticals Inc
- Akari Therapeutics Plc
- Alexion Pharmaceuticals Inc
- Alnylam Pharmaceuticals Inc
- Amgen Inc
- Apellis Pharmaceuticals Inc
- F. Hoffmann-La Roche Ltd
- ISU ABXIS Co Ltd
- Novartis AG
- NovelMed Therapeutics Inc
- Omeros Corp
- Ra Pharmaceuticals Inc
- Regeneron Pharmaceuticals Inc
- Regenesance BV
Highlights of The Paroxysmal Nocturnal Hemoglobinuria Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- ACH-4471
- ALN-CC5
- ALXN-1210
- AMY-101
- APL-2
- Others
- By Application:
- Hospital
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Paroxysmal Nocturnal Hemoglobinuria Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
There is no cure for PNH, but there are treatments that can help manage the disease. Treatment options include medications, blood transfusions, and a range of other therapies. Some people with PNH may need to take multiple treatments over time to manage the disease effectively.
Some of the key players operating in the paroxysmal nocturnal hemoglobinuria treatment market are Achillion Pharmaceuticals Inc, Akari Therapeutics Plc, Alexion Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc, Amgen Inc, Apellis Pharmaceuticals Inc, F. Hoffmann-La Roche Ltd, ISU ABXIS Co Ltd, Novartis AG, NovelMed Therapeutics Inc, Omeros Corp, Ra Pharmaceuticals Inc, Regeneron Pharmaceuticals Inc, Regenesance BV.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Paroxysmal Nocturnal Hemoglobinuria Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Paroxysmal Nocturnal Hemoglobinuria Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Paroxysmal Nocturnal Hemoglobinuria Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Paroxysmal Nocturnal Hemoglobinuria Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size & Forecast, 2018-2028
4.5.1 Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size and Y-o-Y Growth
4.5.2 Paroxysmal Nocturnal Hemoglobinuria Treatment Market Absolute $ Opportunity
Chapter 5 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Forecast by Type
5.2.1 ACH-4471
5.2.2 ALN-CC5
5.2.3 ALXN-1210
5.2.4 AMY-101
5.2.5 APL-2
5.2.6 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Paroxysmal Nocturnal Hemoglobinuria Treatment Analysis and Forecast
9.1 Introduction
9.2 North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Forecast by Type
9.6.1 ACH-4471
9.6.2 ALN-CC5
9.6.3 ALXN-1210
9.6.4 AMY-101
9.6.5 APL-2
9.6.6 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Analysis and Forecast
10.1 Introduction
10.2 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Forecast by Type
10.6.1 ACH-4471
10.6.2 ALN-CC5
10.6.3 ALXN-1210
10.6.4 AMY-101
10.6.5 APL-2
10.6.6 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Forecast by Type
11.6.1 ACH-4471
11.6.2 ALN-CC5
11.6.3 ALXN-1210
11.6.4 AMY-101
11.6.5 APL-2
11.6.6 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Analysis and Forecast
12.1 Introduction
12.2 Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Forecast by Type
12.6.1 ACH-4471
12.6.2 ALN-CC5
12.6.3 ALXN-1210
12.6.4 AMY-101
12.6.5 APL-2
12.6.6 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Paroxysmal Nocturnal Hemoglobinuria Treatment Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Forecast by Type
13.6.1 ACH-4471
13.6.2 ALN-CC5
13.6.3 ALXN-1210
13.6.4 AMY-101
13.6.5 APL-2
13.6.6 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Paroxysmal Nocturnal Hemoglobinuria Treatment Market: Competitive Dashboard
14.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Achillion Pharmaceuticals Inc
14.3.2 Akari Therapeutics Plc
14.3.3 Alexion Pharmaceuticals Inc
14.3.4 Alnylam Pharmaceuticals Inc
14.3.5 Amgen Inc
14.3.6 Apellis Pharmaceuticals Inc
14.3.7 F. Hoffmann-La Roche Ltd
14.3.8 ISU ABXIS Co Ltd
14.3.9 Novartis AG
14.3.10 NovelMed Therapeutics Inc
14.3.11 Omeros Corp
14.3.12 Ra Pharmaceuticals Inc
14.3.13 Regeneron Pharmaceuticals Inc
14.3.14 Regenesance BV
